You have entered the IISP: Interactive Information System on Pathogenomics
If you would like to insert information about your research or research group, please click to the following link to download the form. After filling it out, please send back to email@example.com or firstname.lastname@example.org.
Here you will find information about Research groups in the PathoGenoMics fields from the ERA-NET partner countries (Austria, Finland, France, Hungary, Israel, Latvia, Portugal, Slovenia and Spain).
This information is supposed to support cooperation between researchers from different European countries
and thus enhance the development of a European Research Area for PathoGenoMics .
The following information is available and can be searched for:
- researcher names
- Institution of the respective researcher, city and country of his/her institution
- Contact data of the researcher (address, phone, email)
- Research topics and studied microorganisms of the researcher
- Special techniques applied by the researcher
- Potential cooperation topics suggested by the researcher
If you have any comments/questions or if you would like to add some information, please contact email@example.com
|Name:||Dipl-Ing. Giefing, Carmen|
|Address:||Campus Vienna Biocenter 3 1030 Vienna Austria|
|Institution:||Molecular Microbiology Intercell AG|
|The main focus of our company is the design and development of novel vaccines and therapies for the prevention and treatment of infectious diseases. Our antigenome technology uses a genomic approach to identify novel antigens. The pathogenís genome is fragmented and cloned into an E. coli based surface expression library. This library is then screened for interaction with human antibodies derived from convalescent patients or healthy exposed individuals, thus the ANTIgenome of the pathogen is identified. In a validation procedure based on several in vitro assays we select the most promising candidates for recombinant protein expression and test them for protection in animal models. The aim is to come up with a set of protective, highly conserved and novel proteins, these are then moved forwared towards the devolopment of vaccines and antibody based therapies.|
|Special methods / technologies:|
|Suggestions for potential research cooperations:|